Combination Antibiotics for Staphylococcus aureus Bacteremia in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic interventional study compares combination antibiotic therapy to monotherapy for adults with Staphylococcus aureus bacteremia in hospital settings. High-risk patients may be randomized to receive either monotherapy or combination therapy, while low-risk patients receive usual care. The trial collects data from all eligible SAB patients at participating hospitals to assess outcomes across groups. It includes both MSSA and MRSA bloodstream infections and uses real-world clinical practice as the framework. Patients are followed during hospitalization to evaluate effectiveness and safety of treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
* Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:

  1. on or during the index admission to an IH hospital, or
  2. in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
  3. at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital

     Exclusion Criteria:
* Patient requests that patient health data not be included in the analysis

Where it's running

• Platte Valley Hospital
  Brighton, Colorado, United States Recruiting
• Saint Joseph Hospital
  Denver, Colorado, United States Recruiting
• St. Mary's Regional Hospital
  Grand Junction, Colorado, United States Recruiting
• Good Samaritan Hospital
  Lafayette, Colorado, United States Recruiting
• Lutheran Medical Center
  Wheat Ridge, Colorado, United States Recruiting
• St. Vincent Regional Hospital
  Billings, Montana, United States Recruiting

Study contacts

• Principal investigator: Brandon J Webb, MD — Intermountain Health Care, Inc.
• Study coordinator: Brandon J Webb, MD
• Email: Brandon.Webb@imail.org
• Phone: 801-507-7781

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to dabigatran versus staying on apixaban/edoxaban/rivaroxaban for S. aureus bloodstream infection

  This trial will try whether switching people with S. aureus bloodstream infection who are already taking apixaban, edoxaban, or rivaroxaban to dabigatran leads to better outcomes.

  Recruiting at 3 sites Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · St. John's, Newfoundland and Labrador and 2 other locations · NCT06650501

• Comparing Daptomycin and Vancomycin for MRSA Bloodstream Infections

  This study is testing whether daptomycin or vancomycin works better for treating bloodstream infections caused by MRSA in patients.

  Recruiting at 20 sites Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · Blacktown, New South Wales and 19 other locations · NCT06637332

• Evaluating treatments for Staphylococcus aureus bloodstream infections

  This study is testing different treatments for people with Staphylococcus aureus bloodstream infections to find out which ones work best to help them recover and live longer.

  Recruiting at 126 sites Phase 4 University of Melbourne · Houston, Texas and 160 other locations · NCT05137119

• Combining two antibiotics to treat Staphylococcus aureus bacteremia

  This study is testing if using two antibiotics together can help adults with Staphylococcus aureus bacteremia get better faster than the usual treatment.

  Recruiting at 8 sites Phase 2 McGill University Health Centre/Research Institute of the McGill University Health Centre · Calgary, Alberta and 7 other locations · NCT04886284

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.